x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011943
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val408 of human CYP2D6 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | CYP2D6 |
| UniProt No. | P10635 |
| Gene ID | 1565 |
| Gene Description | Cytochrome P450 2D6 is a member of the cytochrome P450 superfamily of enzymes. CYP2D6 is located in the endoplasmic reticulum where it oxidizes substrates such as drugs and environmental chemicals. CYP2D6 metabolizes more than 25% of current commonly used drugs including antidepressants, antipsychotics, analgesics, beta-adrenergic blocking agents, antiarrythmics, and antiemetics. The CYP2D6 gene is highly polymorphic in humans, resulting in phenotypes that vary from poor metabolizer to super metabolizer. A patient's CYP2D6 genotype was shown to be a good predictor of drug response and side effects and is thus used to guide treatments. Although abundantly expressed in liver, CYP2D6 is also expressed in other organs including brain. In brain, CYP2D6 and other CYP family members are expressed in a cell-specific, region-specific manner. CYP2D6 functions as a neuroprotective enzyme that increases with age and is induced by nicotine and alcohol. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
